Ori Spotlight
Ori Spotlight covers the latest in cell and gene therapy.
Jason C. Foster, Ori Biotech CEO will be talking to leaders from across the industry to find out more about how we can break down the barriers and seize the opportunities to make sure that every patient has access to life-changing treatments.
Connect with Ori Biotech to learn more about partnering to pioneer innovative technologies in CGT manufacturing that bring CGT products to market at commercial scale at decreased costs while increasing throughput and improving quality: www.oribiotech.com/connect
- Update frequency
- every 21 days
- Average duration
- 50 minutes
- Episodes
- 49
- Years Active
- 2021 - 2025
Warner Biddle: Building a commercial model for CAR-T in autoimmune care
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Warner Biddle, CEO of Kyverna Therapeutics, to explore how autologous CAR-T therapies can be delivered safely, efficiently, and …
Lavakumar Karyampudi: Building early-phase CGT infrastructure for translational success
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Lavakumar (Kumar) Karyampudi, Senior Director of Cell Therapies at Moffitt Cancer Center, to discuss how academic institutions a…
Henrik Andersen: How smart planning helps CGT scale further, faster
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Henrik Andersen, former SVP and Head of Cell Therapy Technology Development at Bristol Myers Squibb, to explore how early planni…
Arsalan Arif: Investor confidence in advanced therapies is critical for long-term success
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Arsalan Arif, founder of Endpoints News, for a wide-ranging conversation on the business of biotech. From his early days bootstr…
Julie Allickson: How early automation strategies reduce costs and improve patient access
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Dr. Julie Allickson, Chief Technology Officer for Mayo Clinic's Center for Regenerative Biotherapeutics. With over 30 years pion…
Aaron Vernon: Designing scalable cell therapy manufacturing from day one (part 2)
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes back Aaron Vernon, Chief Manufacturing Officer at Quell Therapeutics, for the second part of the discussion on building robust a…
Aaron Vernon: Designing scalable cell therapy manufacturing from day one (part 1)
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Aaron Vernon, Chief Manufacturing Officer at Quell Therapeutics, for a two-part discussion on building robust and scalable cell …
Amritha Jaishankar: Advancing data integration and decentralized manufacturing for CGT access
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Amritha Jaishankar, Executive Director of the Cell and Gene Therapy Center at IQVIA, to discuss how data integration and decentr…
Boro Dropulić: Simplifying CAR-T workflows will break down barriers to patient access
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Boro Dropulić, CEO of Vector Biomed and Executive Director at Caring Cross.
Boro shares his vision of how decentralized manufact…
Michael Krajewski: How does the Theory of Constraints apply to CGT manufacturing?
In this episode of the Ori Spotlight Podcast, Jason Foster is joined by Michael Krajewski, Director at Stand Back and an expert in engineering and scaling operations. Michael, with his background in …
Carl Schoellhammer: viability is the crucial third pillar in CGT
In this episode, Jason C. Foster welcomes Carl Schoellhammer, Principal & Advanced Therapies Practice Lead at DeciBio, to discuss the importance of considering viability alongside safety and efficacy…
Anshul Mangal: Unlocking scale, automation, digitalization, and standardization in CGT
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Anshul Mangal, President at Project Farma, to discuss the hurdles to scalable CGT development, the importance of early strategic…
Omkar Kawalekar: technology will unlock scalability and patient access
In this episode, Omkar Kawalekar of Deloitte's NextGenTherapies practice joins Ori CEO Jason C. Foster, to explore the significance of technology and strategic collaborations in overcoming manufactur…
Joe DePinto: Bridging growth and accessibility within CGTs
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Joe DePinto, head of Cell and Gene Advanced Therapies at McKesson, to discuss challenges and innovations in cell and gene therap…
Matthew Hewitt: scalability is a collective problem
In this episode of the Ori Spotlight Podcast, Jason C. Foster welcomes Matthew Hewitt, Vice President and Technical Officer of Cell and Gene Therapy and Biologics at Charles River Laboratories, to di…
Adam Siebert & Jeff Holder: early investment in manufacturing is critical for CGT accessibility
In this episode of the Ori Spotlight Podcast, host Jason C. Foster is joined by Jeff Holder and Adam Siebert from LEK Consulting, who offer an in-depth exploration of the evolving cell and gene thera…
Jim Faulkner: Why unaffordable therapy success is worse than failure...
In this episode of Ori Spotlight Podcast, we welcome Jim Faulkner, PhD, Independent Consultant at JDB BioConsulting and former SVP of Product Delivery at Autolus. Jim brings a wealth of experience …
Sanjay Srivastava: Are CGTs Developing into a Commercial Dead-End?
In this episode of the Ori Spotlight Podcast, we're joined by Sanjay Srivastava, Managing Director of Accenture's Cell and Gene Therapy Practice. With his extensive background in consulting and a dee…
Tim Hunt: leading CGT with education and community
We’re joined by Tim Hunt, CEO of Alliance for Regenerative Medicine (ARM). As an international advocacy organization, ARM is a global voice within the cell and gene therapy sector. They champion th…
Vered Caplan: why yesterday’s thinking is not going to solve today’s problems
We’re joined by Vered Caplan, CEO of Orgenesis, as she shares her insights into the cell and gene therapy sector. With a background in engineering and business, Vered found her passion in the cell …